Blog archive
CMC-001 has successfully passed two important milestones
Posted July 04, 2011 by CMC Contrast
At a recent Scientific Advice at EMA in London the agency has concluded that no further non-clinical studies are needed. This means that the non-clinical development program for CMC-001 has successfully been completed.
Another important milestone was reached with the recent finalization of the phase IIb clinical development. In this phase the dose-response relationship for CMC-001 has been established and the final dose for the phase III development program has been selected.
After these two important milestones have been passed the last obstacle is cleared for the targeted liver-specific contrast agent, CMC-001, to enter into phase III clinical studies.
For further information on CMC-001 please contact:
Director of Business Development Thomas Grönberg - E-mail: tg@cmc-contrast.se
or
Director of Medical Affairs Jan Trøst Jørgensen – E-mail: jtj@cmc-contrast.dk
New Publication on CMC-001
Posted August 11, 2010 by CMC Contrast
In the recent edition of Investigative Radiology Dr. Matthias Reif and colleagues at the Charité – Universitätsmedizin in Berlin, Germany have published an article from a phase II with CMC-001 entitled; “Manganese-Based Oral Contrast Agent for Liver Magnetic Resonance Imaging - Evaluation of the Time Course and Dose Response of Liver Signal Intensity Enhancement” (Rief M et al .Invest Radiol 2010; 45).
Based on the results from the study Dr. Reif and colleagues concluded:
“In conclusion, our study demonstrates that CMC-001 administered as single dose is a safe and effective oral contrast agent in patients who undergo MRI for evaluation of liver metastases. Considering the time course of liver SI enhancement and LLC, our results suggest that the diagnostic time window for liver MR imaging is between 2 hours and 6 hours after oral administration of CMC-001. From a logistic standpoint, CMC-001 could simplify liver-specific MR imaging and reduce imaging time and costs...
Oral CMC-001 offers a prolonged diagnostic time window
Posted April 22, 2010 by
At the recent European Congress of Radiology in Vienna new data on the non-gadolinium based oral contrast agent CMC-001 for liver MRI was presented by Dr. Matthias Reif, Institut Für Radiologie, Charité – Universitetätsmedicin, Berlin, Germany. Using multiple MR-imaging for up to 6 hours post contrast, it was shown that already one hour after oral administration of CMC-001 the signal intensity of the liver parenchyma was increased. Increase of liver signal intensity was observed until 3 hours and sustained up to 6 hours after contrast agent administration. Only mild adverse events occurred in 6 out of the 20 patients that participated in the study (1).
With regards to liver MRI, CMC-001 should be considered an alternative to the current gadolinium based contrast agents. Manganese is an essential trace element without risk of nephrogenic systemic fibrosis, and the oral administration route minimizes systemic exposure to manganese (2). Due to the unique formulation of CMC-...
ECR 2010: New Data on CMC-001
Posted February 18, 2010 by Cmc cmc
At the coming European Congress of Radiology in Vienna from March 4 to 8, 2010, new data on the novel non-gadolinium based oral contrast agent for liver MRI will be presented. On March 8 at 2 o’clock in the afternoon data from a clinical phase II study with CMC-001 will be presented by Dr. Matthias Reif, Institut Fûr Radiologie, Charité – Universitetätsmedicin, Berlin, Germany. His presentation will be given in the scientific session “Liver MR: High field and contrast media advantages” and is entitled; “Diagnostic time window for liver MRI after administration of an oral manganese-based contrast agent (CMC-001)”.
For further information on CMC-001 please contact:
Director of Business Development Thomas Grönberg - E-mail:
New Data on CMC-001 to be presented at the coming RSNA meeting
Posted November 12, 2009 by CMC Contrast
At the coming Radiological Society of North America (RSNA) annual meeting in Chicago from November 29 to December 4, 2009, new data on the novel oral contrast agent for liver MRI CMC-001 will be presented. On December 1, 2009 at 10:30 a.m. in the session “Gastrointestinal (Liver MR Imaging: Hepatobiliary Contrast Material Technique)” data from two clinical studies with CMC-001 will be presented. Dr. Helena Dekker, Radboud University Nijmegen Medical Centre, The Netherlands, will give a presentation entitled:
"Oral Manganese as Contrast Medium for MR Imaging Detection of Liver Metastases: A Phase II Clinical Study”.
In the same session Dr. Torkel Brimar, Karolinska University Hospital, Huddinge, Sweden, will present data from another clinical study in a presentation entitled:
“CMC 001: A New Oral Contrast Media to Detect Liver Metastases: Results from a Phase 3 Study”.
For further information please contact:
Dr. Thomas Grönberg, Busin...
